NCT01480050

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the best dose of mibefradil dihydrochloride when given together with temozolomide in treating patients with glioma.

Detailed description

OBJECTIVES: Primary * Determine the maximum-tolerated dose (MTD) of mibefradil dihydrochloride administered prior to five days of temozolomide (TMZ) at 150-200 mg/m² in subjects with progressive or recurrent high-grade glioma. Secondary * Assess the safety of mibefradil dihydrochloride administered prior to five days of TMZ at 150-200 mg/m² when the mibefradil dihydrochloride dose is escalated from a starting dose of 100 mg/day, given four times a day for seven consecutive days. * Determine the pharmacokinetic profile of mibefradil. * Determine the steady state levels of mibefradil dihydrochloride on the last day of dosing. * Assess the severity and frequency of adverse events for tested mibefradil dihydrochloride dose levels including cumulative toxicity and/or tolerance to adverse effects. * Estimate the number and type of radiographic responses to treatment with mibefradil dihydrochloride and temozolomide. * Assess the potential effect of mibefradil dihydrochloride on tumor metabolism as determined by Fluorothymidine Positron Emission Tomography (FLT PET) scans with the radiotracer \[18F\]-3'-fluoro-3'-deoxy-L-thymidine (dose-expansion cohort only). OUTLINE: This is a dose-escalation study of mibefradil dihydrochloride followed by a dose-expansion study. Patients receive mibefradil dihydrochloride orally (PO) 4 times a day on days 1-7 (days 1-8 on first course) and temozolomide PO on days 8-12 (days 9-13 on first course). Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected during the first course for pharmacokinetic studies. Patients in the dose-expansion cohort undergo \[18F\]-3'-fluoro-3'-deoxy-L-thymidine (FLT)-positron emission tomography (PET) at baseline and on day 7 of the first course of therapy. After completion of study therapy, patients are followed up every 2 months.

Conditions

• Brain and Central Nervous System Tumors

Interventions

Type	Name	Description
DRUG	temozolomide	standard of care drug
OTHER	3'-deoxy-3'-[18F]fluorothymidine	tracer used for FLT PET CT
OTHER	pharmacological study
DRUG	Mibefradil

Timeline

• Start date: 2012-05-31
• Primary completion: 2015-08-01
• Completion: 2017-06-01
• First posted: 2011-11-28
• Last updated: 2019-05-22

Locations

7 sites across 1 country: United States